StockData
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.44−0.09 (-5.88%)

Close on Nov 17, 2026Market cap $82.73MP/E –Yield –

Black Diamond Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Black Diamond Therapeutics's pe ratio was 6.8× on Apr 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20266.8×+0.0
2025Dec 31, 20256.8×–

More Black Diamond Therapeutics figures

See a number that looks wrong?